甲磺酸贝舒地尔片全网公布的2024年的最新价格

Introduction: Besudil mesylate tablets are an oral, selective rho-associated coiled-coil protein kinase 2 inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation. Besudil mesylate works by blocking certain immune system reactions that may cause swelling of certain organs or body parts.

The latest price of Besudil mesylate tablets in 2024 announced on the entire Internet

Currently, we know that the price of a box of 200mg*30 tablets is about 47,250$-47,800$ per box, which is relatively expensive. In addition, the price of besudil mesylate tablets produced by Lucius in Laos is relatively low. The current price is about 4050$-4600$ per box, and the specification of a box is 200mg*30 tablets.

It may change due to factors such as drug version, purchase method, etc. The above is for reference only, and the specific price needs to be subject to actual conditions. When purchasing Besudil Mesylate Tablets, you must choose regular channels to avoid buying fake and inferior drugs.

Purchase channels of Besudil mesylate tablets

1. Hospital pharmacies: Besudil mesylate tablets have been launched in China. Patients can go to the hospital for treatment. After the doctor issues the relevant prescription, they can purchase it directly in the hospital pharmacy.

2. Pharmacies: Patients can choose online pharmacies or physical pharmacies to purchase Besudil Mesylate Tablets according to their own circumstances. You may need to show a prescription for Besudil Mesylate Tablets before purchasing.

3. Medical service institutions: If you want to buy generic versions of Besudil Mesylate Tablets, you can purchase them through domestic medical service institutions. After placing the order, you usually get the medicine by mail.

Therapeutic efficacy of Besudil Mesylate Tablets

The efficacy of Besudil Mesylate Tablets was evaluated in a randomized, open-label, multicenter dose-ranging trial. The trial included 65 patients with chronic GVHD who received 200 mg Besudil Mesylate Tablets orally once daily.

The overall response rate (ORR) as of day 1 of cycle 7 was 75%, with 6% of patients achieving complete response (CR) and 69% of patients achieving partial response (PR). The median time to first response was 1.8 months. The median duration of response, measured from first response to progression, death, or initiation of new systemic therapies for chronic GVHD, was 1.9 months. Among patients who achieved a response, 62% did not die or initiate new systemic therapy for at least 12 months after response.

Besudil mesylate tablets treatment can achieve higher ORR and overall survival rate, improve quality of life, reduce CS dose and have limited toxicity. Research data indicate that besudil mesylate tablets may be an effective treatment for patients with refractory cGVHD.